Cocrystal Pharma, Inc.(COCP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

COCP Cocrystal Pharma, Inc.

Trading 01-16 13:47:35 EST

1.11

+0.00

0.00%

High1.14	Low1.11	Vol22.23K
Open1.14	D1 Closing1.11	Amplitude2.70%
Mkt Cap15.30M	Tradable Cap10.38M	Total Shares13.78M
T/O24.88K	T/O Rate0.24%	Tradable Shares9.35M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"COCP","market":"US","secType":"STK","nameCN":"Cocrystal Pharma, Inc.","latestPrice":1.11,"timestamp":1768589214634,"preClose":1.11,"halted":0,"volume":22232,"delay":0,"floatShares":9348900,"shares":13784065,"eps":-0.931673,"marketStatus":"Trading","change":0,"latestTime":"01-16 13:47:35 EST","open":1.138,"high":1.14,"low":1.11,"amount":24879.875664,"amplitude":0.027027,"askPrice":1.12,"askSize":2001,"bidPrice":1.11,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.931673,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1768597200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.11,"preHourTrading":{"tag":"盘前","latestPrice":1.14,"preClose":1.11,"latestTime":"09:07 EST","volume":15,"amount":16.8,"timestamp":1768572446759},"postHourTrading":{"tag":"盘后","latestPrice":1.11,"preClose":1.11,"latestTime":"16:01 EST","volume":80,"amount":88.68,"timestamp":1768510861321},"volumeRatio":0.247225},"requestUrl":"/m/hq/s/COCP/tweets","defaultTab":"tweets","newsList":[{"id":"2603593518","title":"Cocrystal Pharma Grants Stock Options to Directors and Executives Under New Equity Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2603593518","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603593518?lang=en_us&edition=fundamental","pubTime":"2026-01-16 05:11","pubTimestamp":1768511501,"startTime":"0","endTime":"0","summary":"Cocrystal Pharma Inc. has approved new compensation terms for its directors, executive officers, and a consultant, effective January 9, 2026. The Compensation Committee granted non-qualified stock options under the company's 2025 Equity Incentive Plan, with a 10-year term and an exercise price set at the closing price on January 8, 2026. The options will vest in two parts: half on January 9, 2027, and the remainder in eight equal quarterly installments starting March 31, 2027, contingent on continued service. Notably, Dr. Roger Kornberg and Dr. Philip Frost each received a total of 24,615 stock options, reflecting additional grants for serving as chairman and lead director, respectively. In addition, Dr. Kornberg was awarded a $50,000 cash payment for his role as chairman of the Scientific Advisory Board.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL3f47Zn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COCP","BK4007"],"gpt_icon":0},{"id":"2600701861","title":"Director and 10% Owner Phillip Frost Reports Acquisition of Cocrystal Pharma Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701861","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600701861?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:10","pubTimestamp":1767215451,"startTime":"0","endTime":"0","summary":"Phillip Frost, MD, a Director and 10% Owner, reported the acquisition of common shares of Cocrystal Pharma Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 31, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL2RPKcK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director and 10% Owner Phillip Frost Reports Acquisition of Cocrystal Pharma Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COCP","BK4007"],"gpt_icon":0},{"id":"2592544909","title":"BRIEF-Cocrystal Pharma Receives Irb Approval From Emory University School Of Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2592544909","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592544909?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:30","pubTimestamp":1766064605,"startTime":"0","endTime":"0","summary":"BRIEF-Cocrystal Pharma Receives Irb Approval From Emory University School Of Medicine Dec 18 (Reuters) - Cocrystal Pharma Inc COCP.O:COCRYSTAL PHARMA RECEIVES IRB APPROVAL FROM EMORY UNIVERSITY SCHOOL","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUAB8JXV4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","COCP"],"gpt_icon":0},{"id":"2592906572","title":"Cocrystal Pharma Receives IRB Approval for Phase 1b Norovirus Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2592906572","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592906572?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:02","pubTimestamp":1766062947,"startTime":"0","endTime":"0","summary":"Cocrystal Pharma Inc. has received approval from the Institutional Review Board  at Emory University School of Medicine to initiate a Phase 1b human challenge study with its oral antiviral drug candidate, CDI-988, for the prevention and treatment of norovirus infections. This follows earlier clearance from the U.S. Food and Drug Administration  of Cocrystal’s investigational New Drug  application. Subject enrollment for the study is expected to begin in the first quarter of 2026. No grant or funding involving multiple organizations is mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief via GlobeNewswire  on December 18, 2025, and is solely respo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL4LW4d9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","BK4588","SG9999014039.USD","BK4112","LU2210150020.SGD","BK4007","LU2210149790.SGD","COCP","LU2095319765.USD","SG9999014013.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014021.USD","BK4585"],"gpt_icon":0},{"id":"2592690638","title":"Cocrystal Pharma Receives Irb Approval From Emory University School of Medicine for Phase 1B Human Challenge Study With Cdi-988 for Prevention and Treatment of Norovirus","url":"https://stock-news.laohu8.com/highlight/detail?id=2592690638","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592690638?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:00","pubTimestamp":1766062805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUAB8JXV4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COCP","BK4007"],"gpt_icon":0},{"id":"2592290668","title":"Cocrystal Pharma Inc - Subject Enrollment for Study Expected to Begin in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592290668","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592290668?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:00","pubTimestamp":1766062805,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUAB8JXV4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","COCP"],"gpt_icon":0},{"id":"2588777917","title":"Cocrystal Pharma Inc. unveils investor presentation highlighting advances in broad-spectrum antiviral drug development","url":"https://stock-news.laohu8.com/highlight/detail?id=2588777917","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588777917?lang=en_us&edition=fundamental","pubTime":"2025-12-02 03:08","pubTimestamp":1764616090,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief on December 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL7dcNTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COCP","BK4007"],"gpt_icon":0},{"id":"2586285549","title":"Cocrystal Pharma Director and 10% Owner Phillip Frost Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586285549","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586285549?lang=en_us&edition=fundamental","pubTime":"2025-11-26 09:17","pubTimestamp":1764119852,"startTime":"0","endTime":"0","summary":"Phillip Frost, MD, a Director and 10% Owner, reported the acquisition of common shares of Cocrystal Pharma Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL33hHxv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cocrystal Pharma Director and 10% Owner Phillip Frost Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COCP","BK4007"],"gpt_icon":0},{"id":"2583291509","title":"Cocrystal Pharma Receives FDA Clearance and NIH Grant to Advance Norovirus and Influenza Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2583291509","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583291509?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:31","pubTimestamp":1763127083,"startTime":"0","endTime":"0","summary":"Cocrystal Pharma Inc. announced it has received clearance from the U.S. Food and Drug Administration  to proceed with a Phase 1b clinical trial of its oral broad-spectrum protease inhibitor, CDI-988, for both the prevention and treatment of norovirus infection. Additionally, the company was awarded a Small Business Innovation Research  grant from the National Institutes of Health  to advance its influenza A/B replication inhibitor program. These developments support Cocrystal Pharma's ongoing efforts to address unmet needs in antiviral therapies. There is no indication that the grant was obtained by organizations other than Cocrystal Pharma.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original con","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL7xPyMl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COCP","BK4007"],"gpt_icon":0},{"id":"2583506204","title":"Cocrystal Pharma Q3 loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2583506204","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583506204?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:08","pubTimestamp":1763125732,"startTime":"0","endTime":"0","summary":"Cocrystal Pharma Q3 loss narrowsOverviewCocrystal Pharma Q3 net loss decreases to $2 mln from $4.9 mln yr/yrCompany received FDA clearance for CDI-988 Phase 1b norovirus study starting Q1 2026Company ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL1N3WQ0IZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COCP","BK4007"],"gpt_icon":0},{"id":"2583069765","title":"BRIEF-Cocrystal Pharma Q3 Net Income USD -2.049 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583069765","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583069765?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:00","pubTimestamp":1763125247,"startTime":"0","endTime":"0","summary":"BRIEF-Cocrystal Pharma Q3 Net Income USD -2.049 Million\n\n\nNov 14 (Reuters) - Cocrystal Pharma Q3 operating expenses USD 2.089 million.\n\nQ3 basic EPS USD -0.19\nQ3 operating income USD -2.089 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLXEA626D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COCP","BK4007"],"gpt_icon":0},{"id":"2583506641","title":"Cocrystal Pharma Q3 Basic EPS USD -0.19","url":"https://stock-news.laohu8.com/highlight/detail?id=2583506641","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583506641?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:00","pubTimestamp":1763125202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLXEA626D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COCP","BK4007"],"gpt_icon":0},{"id":"2583506432","title":"Cocrystal Pharma Inc - Phase 1B Norovirus Study for Cdi-988 Expected in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2583506432","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583506432?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:00","pubTimestamp":1763125202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLXEA626D:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COCP","BK4007"],"gpt_icon":0},{"id":"2583066005","title":"Cocrystal Pharma Q3 Operating Expenses USD 2.089 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583066005","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583066005?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:00","pubTimestamp":1763125202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLXEA626D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","COCP"],"gpt_icon":0},{"id":"2581920881","title":"Cocrystal Pharma Inc  expected to post a loss of 21 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581920881","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581920881?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:50","pubTimestamp":1762527020,"startTime":"0","endTime":"0","summary":"Cocrystal Pharma Inc  expected to post a loss of21cents a share - Earnings Preview Cocrystal Pharma Inc COCP.OQ COCP.O is expected to  show no change in quarterly revenue when it reports  results on N","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ20O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","COCP"],"gpt_icon":0},{"id":"2579736145","title":"Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2579736145","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579736145?lang=en_us&edition=fundamental","pubTime":"2025-10-30 20:00","pubTimestamp":1761825606,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUABZLDGC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COCP","BK4007"],"gpt_icon":0},{"id":"2577588135","title":"Noble Financial Remains a Buy on Cocrystal Pharma (COCP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2577588135","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577588135?lang=en_us&edition=fundamental","pubTime":"2025-10-23 21:55","pubTimestamp":1761227716,"startTime":"0","endTime":"0","summary":"In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Cocrystal Pharma, with a price target of $10.00. The com...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/noble-financial-remains-a-buy-on-cocrystal-pharma-cocp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/noble-financial-remains-a-buy-on-cocrystal-pharma-cocp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COCP","NBL","BK4007"],"gpt_icon":0},{"id":"2574419818","title":"Cocrystal Pharma Inc publishes investor presentation on advancing broad spectrum antiviral drug candidates for influenza norovirus and coronavirus","url":"https://stock-news.laohu8.com/highlight/detail?id=2574419818","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574419818?lang=en_us&edition=fundamental","pubTime":"2025-10-10 01:58","pubTimestamp":1760032698,"startTime":"0","endTime":"0","summary":"Cocrystal Pharma Inc publishes investor presentation on advancing broad spectrum antiviral drug candidates for influenza norovirus and coronavirus. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief on October 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDLb9v72c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COCP","BK4007"],"gpt_icon":0},{"id":"2568291844","title":"Cocrystal Pharma files to sell 5.74M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2568291844","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568291844?lang=en_us&edition=fundamental","pubTime":"2025-09-20 04:35","pubTimestamp":1758314111,"startTime":"0","endTime":"0","summary":"16:32 EDT Cocrystal Pharma (COCP) files to sell 5.74M shares of common stock for holders Published first on TheFly – the ultimate source for real-t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cocrystal-pharma-files-to-sell-5-74m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cocrystal-pharma-files-to-sell-5-74m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COCP","BK4007"],"gpt_icon":0},{"id":"2567147930","title":"Cocrystal Pharma Inc. Completes $13 Million Direct Offering with Warrants for Additional Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2567147930","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567147930?lang=en_us&edition=fundamental","pubTime":"2025-09-16 04:36","pubTimestamp":1757968573,"startTime":"0","endTime":"0","summary":"Cocrystal Pharma, Inc., a biotechnology company, has announced the closing of a registered direct offering, generating up to $13 million in gross proceeds. The offering includes the sale of 2,764,710 shares of common stock priced at $1.70 per share, raising $4.7 million upfront. Additionally, unregistered warrants have been issued through a concurrent private placement, allowing the purchase of up to 5,529,420 shares of common stock at an exercise price of $1.50 per share. These warrants are exercisable immediately and will expire 24 months from the effective date of the registration statement. H.C. Wainwright & Co. acted as the exclusive placement agent for this offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL4w38X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COCP","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cocrystalpharma.com","stockEarnings":[{"period":"1week","weight":0.0091},{"period":"1month","weight":0.1283},{"period":"3month","weight":0.0374},{"period":"6month","weight":-0.3232},{"period":"1year","weight":-0.4478},{"period":"ytd","weight":0.1338}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.103},{"period":"1year","weight":0.1678},{"period":"ytd","weight":0.0151}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.086629},{"month":2,"riseRate":0.142857,"avgChangeRate":0.063344},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.113434},{"month":4,"riseRate":0.5,"avgChangeRate":-0.032655},{"month":5,"riseRate":0.5,"avgChangeRate":0.034182},{"month":6,"riseRate":0.875,"avgChangeRate":0.166825},{"month":7,"riseRate":0.5,"avgChangeRate":0.027465},{"month":8,"riseRate":0.375,"avgChangeRate":-0.066821},{"month":9,"riseRate":0,"avgChangeRate":-0.1868},{"month":10,"riseRate":0.125,"avgChangeRate":-0.206494},{"month":11,"riseRate":0.75,"avgChangeRate":0.316208},{"month":12,"riseRate":0.125,"avgChangeRate":-0.139649}],"exchange":"NASDAQ","name":"Cocrystal Pharma, Inc.","nameEN":"Cocrystal Pharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cocrystal Pharma, Inc.(COCP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cocrystal Pharma, Inc.(COCP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cocrystal Pharma, Inc.,COCP,Cocrystal Pharma, Inc.股票,Cocrystal Pharma, Inc.股票老虎,Cocrystal Pharma, Inc.股票老虎国际,Cocrystal Pharma, Inc.行情,Cocrystal Pharma, Inc.股票行情,Cocrystal Pharma, Inc.股价,Cocrystal Pharma, Inc.股市,Cocrystal Pharma, Inc.股票价格,Cocrystal Pharma, Inc.股票交易,Cocrystal Pharma, Inc.股票购买,Cocrystal Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cocrystal Pharma, Inc.(COCP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cocrystal Pharma, Inc.(COCP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction